Gosogliptin

Summary

Gosogliptin (CHEMBL515387) is an approved small molecule; indicated across 2 conditions including type 2 diabetes mellitus and chronic kidney disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 366.4 Da · C17H24F2N6O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL515387
Name	Gosogliptin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	11516136
Molecular formula	C17H24F2N6O
Molecular weight	366.4
InChIKey	QWEWGXUTRTXFRF-KBPBESRZSA-N

SMILES: C1CN(CC1(F)F)C(=O)[C@@H]2C[C@@H](CN2)N3CCN(CC3)C4=NC=CC=N4

IUPAC name: (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone

Also known as: Gosogliptin, Gosogliptina, Gosogliptine, PF-00734200, PF-734,200, PF-734200, GOSOGLIPTIN

Parent form; salt/anhydrous children: CHEMBL3526419

Patent coverage: 254 distinct patent families (785 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Dipeptidyl peptidase 4, Dipeptidyl peptidase 2, Dipeptidyl peptidase 4, Dipeptidyl peptidase 8, Prolyl endopeptidase FAP, Dipeptidyl peptidase 9.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DPP4	7.95	IC50	11.3	nM	CHEMBL_ACT_2516375
DPP4	7.89	IC50	12.9	nM	CHEMBL_ACT_12588815
DPP4	7.89	IC50	12.9	nM	CHEMBL_ACT_2515605
P14740	7.89	IC50	12.8	nM	CHEMBL_ACT_2516376
DPP7	5.48	IC50	3300	nM	CHEMBL_ACT_2515624
DPP9	5.22	IC50	5980	nM	CHEMBL_ACT_2515564
DPP8	5.16	IC50	7000	nM	CHEMBL_ACT_2515643

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
chronic kidney disease	1	MONDO:0005300	EFO:0003884

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03088670	PHASE3	COMPLETED	Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
NCT00596518	PHASE1	COMPLETED	A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).